glp 1 cgm Abbott data suggests GLP-1 drugs a 'modest accelerator' for CGMs: analysts GLP-1-based therapies for type 2

On September 11, Eli Lilly filed a motion seeking to centralize all federal lawsuits alleging vision loss (NAION) linked to GLP-1RAs

Last Published 04.01.2026 Effective Date: 04.01.2026 This policy addresses upper extremity myoelectric prosthetic devices

At HormoneSynergy Clinic in Portland and Lake Oswego, we view GLP-1 therapy as one possible tool inside a broader longevity medicine model, not as a shortcut around the systems that actually shape brain health over decades

Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2025 increased slightly relative to September 2025 (+5.0%) and now account for more than 7% of all prescriptions